Search research articles
Contact Us
Filters
Showing results (41-50 of 101) with videos related to
Page
of 11
Sort By:
British Journal of Cancer
|
February 25, 2016
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
Martin H Voss, David Chen, Mahtab Marker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2020
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H Taylor, Chung-Han Lee, Vicky Makker, et al.
JCO Precision Oncology
|
February 9, 2022
<i>ALK</i> Fusions in Renal Cell Carcinoma: Response to Entrectinib
Jessica J Tao, Ge Wei, Roopal Patel, et al.
Frontiers in Oncology
|
July 15, 2022
Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma
David S Tourigny, Mark Zucker, Minsoo Kim, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 4, 2025
Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma
Yasser Ged, Amina Touma, Luis Meza Contreras, et al.
Clinical Genitourinary Cancer
|
September 26, 2015
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs
Chung-Han Lee, Andreas M Hötker, Martin H Voss, et al.
The Oncologist
|
June 12, 2016
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
Maria I Carlo, Ana M Molina, Yulia Lakhman, et al.
British Journal of Cancer
|
October 7, 2020
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
Chung-Han Lee, Robert J Motzer, Hilary Glen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 3, 2021
Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors
Jose Mauricio Mota, Min Yuen Teo, Karissa Whiting, et al.
British Journal of Clinical Pharmacology
|
April 22, 2005
Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism
Ji-Hong Shon, Young-Ran Yoon, Min-Jung Kim, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 101) with videos related to
Sort By:
Page
of 11
British Journal of Cancer
|
February 25, 2016
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
Martin H Voss, David Chen, Mahtab Marker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2020
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H Taylor, Chung-Han Lee, Vicky Makker, et al.
JCO Precision Oncology
|
February 9, 2022
<i>ALK</i> Fusions in Renal Cell Carcinoma: Response to Entrectinib
Jessica J Tao, Ge Wei, Roopal Patel, et al.
Frontiers in Oncology
|
July 15, 2022
Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma
David S Tourigny, Mark Zucker, Minsoo Kim, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 4, 2025
Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma
Yasser Ged, Amina Touma, Luis Meza Contreras, et al.
Clinical Genitourinary Cancer
|
September 26, 2015
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs
Chung-Han Lee, Andreas M Hötker, Martin H Voss, et al.
The Oncologist
|
June 12, 2016
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
Maria I Carlo, Ana M Molina, Yulia Lakhman, et al.
British Journal of Cancer
|
October 7, 2020
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
Chung-Han Lee, Robert J Motzer, Hilary Glen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 3, 2021
Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors
Jose Mauricio Mota, Min Yuen Teo, Karissa Whiting, et al.
British Journal of Clinical Pharmacology
|
April 22, 2005
Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism
Ji-Hong Shon, Young-Ran Yoon, Min-Jung Kim, et al.
Page
of 11